Entera Bio Beats Q2 EPS Estimates
Entera Bio (NASDAQ:ENTX), a clinical-stage biotech specializing in oral delivery of protein and peptide drugs, released its earnings for the second quarter of fiscal 2025 on August 8, 2025. The most notable news was a better-than-expected GAAP earnings per share of $0.06, compared to Wall Street estimates for a GAAP loss of $(0.11). No revenue was reported for the period, compared to $57,000 in GAAP revenue in Q2 2024. The overall quarter was defined by a major regulatory breakthrough for Entera Bio's lead candidate EB613, ongoing advancement in its product pipeline, and prudent financial management to extend its cash runway.
Source: Analyst estimates for the quarter provided by FactSet.
Entera Bio is working to solve a key challenge in pharmaceutical development: how to deliver protein-based drugs, like peptides, by mouth instead of injection. Its core platform—N-Tab™ technology—makes peptides stable in the digestive tract and helps them be absorbed into the bloodstream. This technology forms the foundation of the company's most advanced products and many of its collaborations with other pharmaceutical developers.
Source Fool.com
